Features of cytokine status dynamics in patients with COVID-19 using Ambervin® Pulmo; [Особенности динамики цитокинового статуса пациентов с COVID-19 на фоне применения препарата Амбервин® Пульмо]

The purpose of the study was to study cytokine-mediated effects in patients with coronavirus disease 2019 (COVID-19) when using the drug Ambervin® Pulmo. Material and methods. The study included patients with moderate laboratory-confirmed COVID-19. Three groups were formed: group 1 - therapy in accordance with the Temporary Methodological Recommendations, group 2 - in addition to cessation of therapy, the drug Ambervin® Pulmo was administered intramuscularly; group 3 - the drug Ambervin® Pulmo is indicated for inhalation. Analysis of the dynamics of the content of cytokines [interferon alpha (IFN-α), interferon beta (IFN-β), interleukins (IL-1β, IL-6), tumor necrosis factor-alpha (TNF-α), high-mobility group protein B1 (HMGB1)]. Statistics of the results were carried out using the StatTech v program. 2.8.8. A prognostic model based on the linear regression method is proposed. Differences were considered statistically significant at p<0.05. Results and discussion. The inclusion of the drug Ambervin® Pulmo in the treatment regimen for COVID-19 (regardless of the form of its administration) led to an increase in IFN-β in the blood along with a decrease in the level of HMGB1, which partially reduces the risks of developing cardiovascular complications in the recovery period. The use of the drug Ambervin® Pulmo in patients with COVID-19 reduced the length of hospitalization of patients. Considering the pathogenetic role of the identified markers of the antiviral immune response, additional studies on the use of the drug Ambervin® Pulmo in patients with various viral diseases, in particular viral hepatitis, can be considered promising. Conclusion. The results of the study and previously published data expand the scientific understanding of changes in cytokine regulation while taking the drug Ambervin® Pulmo. © 2023 Geotar Media Publishing Group. All rights reserved.